Current Report Filing (8-k)
07 12월 2012 - 1:56AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December
6, 2012
SYNTHETIC BIOLOGICS, INC.
(Exact name of registrant as specified in
its charter)
Nevada
|
|
1-12584
|
|
13-3808303
|
(State or other jurisdiction of incorporation)
|
|
(Commission File No.)
|
|
(IRS Employer Identification No.)
|
617 Detroit Street, Suite 100, Ann Arbor,
Michigan 48104
(Address of principal executive offices) (Zip
Code)
Registrant’s telephone number, including
area code: (734) 332-7800
(Former name or former address, if changed
since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 7.01.
|
Regulation FD Disclosure
|
Jeffrey Riley, Chief Executive Officer and President of Synthetic
Biologics, Inc. (the “Company”), will be presenting at the LD MICRO Conference in Los Angeles, CA, as well as making
several investor presentations during the next few weeks, the first of which will be on December 6, 2012. In connection with the
presentations, Mr. Riley intends to discuss the slide presentation furnished as Exhibit 99.1 hereto, which is incorporated herein
by reference.
The slide presentation attached as Exhibit
99.1 to this Report includes “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995,
as amended, indicating that certain statements contained in the slide presentation are “forward-looking” rather than
historical.
The information included in this Item 7.01
and in Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or otherwise subject to the liabilities of that Section or incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference
in such a filing. The Company undertakes no duty or obligation to update or revise information included in this Report or the Exhibit.
|
Item 9.01.
|
Financial Statements and Exhibits
|
The following exhibit
is being filed as part of this Report.
Exhibit
Number
|
Description
|
|
|
99.1
|
Presentation materials to be provided at the Synthetic Biologics, Inc.’s investor presentations.
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
SYNTHETIC BIOLOGICS, INC.
|
|
|
Date: December 6, 2012
|
By:
/s/ C. Evan Ballantyne
|
|
Name: C. Evan Ballantyne
|
|
Title: Chief Financial Officer
|
EXHIBIT INDEX
Exhibit
Number
|
Description
|
|
|
99.1
|
Presentation materials to be used at Synthetic Biologics, Inc.’s investor presentations.
|
Synthetic Biologics (AMEX:SYN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Synthetic Biologics (AMEX:SYN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Synthetic Biologics Inc (아메리카 증권거래소)의 실시간 뉴스: 최근 기사 0
More Synthetic Biologics, Inc. News Articles